Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149481 | 0.88 | CHRM3 (0.46) | KCNH2ACHEFUCA1GRIN2B | |
| SCHEMBL4141323 | 0.88 | ACHE (0.44) | KCNH2ACHEFUCA1GRIN2BS1PR1 | |
| SCHEMBL7242578 | 0.83 | FUCA1 (0.50) | ACHEFUCA1GRIN2BS1PR1S1PR5 | |
| SCHEMBL7248714 | 0.81 | FUCA1 (0.46) | ACHEFUCA1GRIN2BS1PR1S1PR5 | |
| SCHEMBL3527474 | 0.80 | GRIN2B (0.45) | ACHEFUCA1GRIN2BS1PR1S1PR5 | |
| SCHEMBL4136255 | 0.77 | OPRM1 (0.46) | ACHEFUCA1GRIN2B | |
| SCHEMBL4619946 | 0.76 | ACHE (0.43) | KCNH2ACHEFUCA1S1PR1S1PR5 | |
| SCHEMBL2300893 | 0.76 | ACHE (0.49) | ACHEFUCA1DRD2SIGMAR1 | |
| SCHEMBL4190924 | 0.75 | CHRM3 (0.51) | ACHEGRIN2BS1PR1S1PR5 | |
| SCHEMBL12371118 | 0.71 | FUCA1 (0.68) | ACHEFUCA1GRIN2BS1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | claimed |
| EP-1934184-A1 | 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-06-25 | — | — | EP | claimed |
| WO-2007039884-A1 | 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-12 | — | — | WO | claimed |
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1934184-A1 | 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039884-A1 | 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | KCNH2 797/4885ACHE 129/4885FUCA1 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.